Introduction
============

Ovarian cancer remains the most lethal gynecologic malignancy, with \~22,000 new cases and 14,000 deaths estimated in 2018 in the US alone [@B1]. Despite substantial progress in diagnosis and therapy over the years, the overall 5-year survival rate remains extremely low at 25-35% [@B2] owing to the considerable difficulty in detecting the disease at the early stages [@B3] and common development of resistance to cisplatin- or carboplatin-based chemotherapy [@B4]. As a result, fewer than 15% of patients respond to further treatment [@B4], leading to an average progression-free survival (PFS) of 3-4 months and median overall survival (OS) of 9-12 months [@B5]. The molecules and genetic factors that drive the development of chemoresistance are yet to be established, which presents a major obstacle in preventing and predicting clinical chemoresistance.

Various cell lines are available for modeling chemoresistance of ovarian cancer due to the characteristics of easy operation and stable culture. However, cancer cell clusters in tumor tissues are heterogeneous, which is important for the evolution-associated tumor microenvironment (TME) and chemoresistance. Since ovarian cancer tissues comprise a wide spectrum of distinct molecules and clinical entities [@B6], cell lines derived from single clones are unable to effectively model the TME and organ functions. An organoid is a three-dimensional multicellular structure with microanatomical features of its source organs [@B7]. More recently, patient-derived organoids (PDO) representing tumor-relevant physiology and pathology have been successfully applied to achieve rapid assaying of phenotype-genotype correlations and drug sensitivity in many tumor types [@B8]-[@B10], offering an exceptional model to study cancer chemoresistance.

The serine/threonine kinase, Aurora-A, is a member of the Aurora kinase family reported to induce centrosome amplification, spindle formation, chromosomal instability and transformation in mammalian cells [@B11],[@B12]. The protein is frequently overexpressed and/or amplified in various cancer types, including breast cancer [@B13], pancreatic cancer [@B14] and ovarian cancer [@B11], and its upregulation was shown to be associated with drug resistance and poorer prognosis [@B15]-[@B17]. Conversely, interference with Aurora-A expression is reported to sensitize tumor cells to antineoplastic treatments [@B18],[@B19], highlighting its potential utility as a promising chemotherapeutic target [@B20]-[@B23].

In this study, we established organoids from both cisplatin-sensitive and -resistant ovarian cancer tissues. RNA sequencing revealed significant upregulation of Aurora-A in cisplatin-induced resistant PDOs. Furthermore, Aurora-A promoted cisplatin resistance via regulation of cell senescence and glucose metabolism in PDOs, cells and tumor-transplanted mice. Data from mechanistic analyses showed that Aurora-A bound directly to the transcription factor sex determining region Y-box 8 (SOX8) and phosphorylated its Ser327 site, thereby activating forkhead-box k1 (FOXK1) with consequent effects on cell senescence, glycolysis, and chemoresistance. Our collective findings disclose a previously unrecognized mechanism of chemoresistance in ovarian cancer, which provides novel therapeutic targets that may be effective in preventing tumor chemoresistance and progression.

Results
=======

Cisplatin resistance is closely associated with cell senescence and glucose metabolism in organoids of ovarian cancer
---------------------------------------------------------------------------------------------------------------------

To explore the potential mechanisms underlying ovarian cancer chemoresistance, we established PDOs using cisplatin-sensitive and -resistant ovarian cancer tissues and verified their chemosensitivity to cisplatin (**Figure [1](#F1){ref-type="fig"}A-B**). RNA sequencing was employed to compare expression of chemosensitivity-related genes in 4 cisplatin-sensitive and 6 cisplatin-resistant PDOs. Notably, levels of a number of important regulatory genes involved in cell senescence were decreased while those of several genes involved in glycolysis were significantly increased (**Figure [1](#F1){ref-type="fig"}C**), as confirmed with SA-β-gal (**Figure [1](#F1){ref-type="fig"}D**) and patient PET/CT scans (**Figure [1](#F1){ref-type="fig"}E**). The SUV~max~ values of ovarian cancer patients subjected to PET/CT were additionally assessed. The average value for cisplatin-resistant patients was 17.23 while that for cisplatin-sensitive patients was 10.75 (**Figure [1](#F1){ref-type="fig"}F**). Overall, high SUV~max~ values associated with poorer overall survival (**Figure [1](#F1){ref-type="fig"}G**). Data from the glucose metabolism assay showed an obvious increase in metabolites of glycolysis in cisplatin-resistant PDOs (**Figure [1](#F1){ref-type="fig"}H**). Subsequent qRT-PCR performed to detect mRNA expression of cisplatin-sensitive and -resistant PDOs revealed that levels of several genes inducing cell senescence, such as p53, p16 and p21, were decreased in cisplatin-resistant PDOs while those participating in glycolysis, such as HK2, GLUT1 and LDHA, were significantly increased (**Figure [1](#F1){ref-type="fig"}I-J**), clearly indicating critical involvement of cell senescence and glycolysis in chemoresistance of ovarian cancer.

Chemoresistance of ovarian cancer was induced by Aurora-A high expression
-------------------------------------------------------------------------

To distinguish chemoresistance-associated genes, RNA sequencing assays were conducted, which led to the identification of Aurora-A as a potential crucial regulator in cisplatin-resistant PDOs (**Figure [2](#F2){ref-type="fig"}A**). Data from immunofluorescence analyses showed markedly higher Aurora-A expression in cisplatin-resistant PDOs relative to the control group (**Figure [2](#F2){ref-type="fig"}B**), which was further confirmed via qRT-PCR of tumor tissues (**[Figure S1](#SM0){ref-type="supplementary-material"}A**). To investigate the functions and mechanisms of action of Aurora-A in chemoresistance, we established ovarian cancer cell lines, OVCA429 and SKOV3, overexpressing Aurora-A. Interestingly, upregulation of Aurora-A significantly attenuated sensitivity of cells to cisplatin (F**igure S1B-C**). We subsequently generated cisplatin-resistant cell lines, OVCA429-CisR and SKOV3-CisR (**[Figure S1](#SM0){ref-type="supplementary-material"}D**) for examination of Aurora-A expression. Immunoblot analyses showed significant expression of Aurora-A in both OVCA429-CisR and SKOV3-CisR cell lines (**[Figure S1](#SM0){ref-type="supplementary-material"}E**). Subcellular localization analysis verified that cytoplastic Aurora-A levels were significantly increased in chemoresistant ovarian cancer cells while nuclear Aurora-A was only slightly affected (**[Figure S1](#SM0){ref-type="supplementary-material"}F-H**). The effects of Aurora-A silencing on cell viability and apoptosis were further examined by transfection of two shRNA vectors of Aurora-A into OVCA429-CisR and SKOV3-CisR cell lines (**Figure [2](#F2){ref-type="fig"}C**). Notably, knockdown of Aurora-A significantly suppressed viability in ovarian cancer cells, as observed from CCK-8 experiments (**[Figure S1](#SM0){ref-type="supplementary-material"}I**). Next, we examined whether Aurora-A expression and activity are associated with cisplatin resistance in ovarian cancer cells. To this end, MLN8237 was used to selectively inhibit Aurora-A activity and the effects were confirmed via immunoblotting of p-Aurora-A (Thr288) (**[Figure S1](#SM0){ref-type="supplementary-material"}J**). Compared with the corresponding control cells, the half-maximal inhibitory concentration (IC~50~) of cisplatin was decreased in OVCA429-CisR cells by 30.41%, 28.88% and 35.11% after Aur-i1, Aur-i2 and MLN8237 treatment; IC~50~ was decreased in SKOV3-CisR cells by 33.65%, 26.60% and 33.08% after Aur-i1, Aur-i2 and MLN8237 treatment compared with their controls (**Figure [2](#F2){ref-type="fig"}D-E**).

By Flow Cytometry we found that the number of apoptotic cells induced by 5ug/mL cisplatin for 48h in OVCA429-CisR was increased by 17.27%, 16.09% and 12.07%, respectively, after Aur-i1, Aur-i2 and MLN8237 treatment; in SKOV3-CisR the number of apoptotic cells was increased by 14.93%, 15.13%, and 9.63% after Aur-i1, Aur-i2 and MLN8237 treatment compared with their controls (**Figure [2](#F2){ref-type="fig"}F-G and [Figure S1](#SM0){ref-type="supplementary-material"}K**). And in comparison with MLN8237 alone, combination treatment with cisplatin increased apoptosis by 9.59% in OVCA429/CisR cells and 5.07% in SKOV3-CisR cells. Moreover, wild-type Aurora-A overexpression led to reversal of chemosensitivity caused by Aurora-A silencing (**[Figure S2](#SM0){ref-type="supplementary-material"}A-F**), clearly signifying a critical role of this protein in mediating chemoresistance of ovarian cancer cells.

Aurora-A suppresses cell senescence and promotes glycolysis in ovarian cancer cells
-----------------------------------------------------------------------------------

Since chemoresistance appears to be associated with low senescence in PDOs of ovarian cancer, senescent ovarian cancer cells were established for further study. Chemoresistance was effectively reversed in the senescent group, compared with the control (**[Figure S3](#SM0){ref-type="supplementary-material"}A-C**). Moreover, SA-β-gal activity was increased in Aurora-A knockdown cells after 15 passages (**[Figure S3](#SM0){ref-type="supplementary-material"}D**) or treatment with cisplatin (**Figure [2](#F2){ref-type="fig"}H-I and [Figure S3](#SM0){ref-type="supplementary-material"}E**). Immunofluorescence and immunoblotting experiments demonstrated that Aurora-A knockdown increased apoptosis and senescence-associated proteins, such as P16, concomitant with a significant decrease in hTERT (**Figures [2](#F2){ref-type="fig"}J and S3F**).

Since chemoresistance is associated with high glycolysis in PDOs of ovarian cancer, we investigated this association in ovarian cancer cells. As expected, chemoresistant ovarian cancer cells exhibited higher glycolysis phenotypes, compared to their parental cells (**[Figure S4](#SM0){ref-type="supplementary-material"}A-F**). To validate these results, chemoresistant ovarian cancer cells were treated with the glycolysis inhibitor 2-DG (5 mM for 48 h), which led to significant reversal of cisplatin resistance (**[Figure S4](#SM0){ref-type="supplementary-material"}G-H**). Subsequently, cellular glycolysis assays were conducted to examine the effects of Aurora-A on glucose metabolism in ovarian cancer cells. Glycolytic phenotypes were clearly increased under conditions of Aurora-A upregulation (**[Figure S4](#SM0){ref-type="supplementary-material"}I-N**) while Aurora-A silencing inhibited glycolysis to a significant extent (**Figure [3](#F3){ref-type="fig"}A-F**).

Immunoblotting and immunofluorescence experiments further revealed that Aurora-A knockdown led to reduced expression of glycolysis-related proteins, such as LDHA and HK2, in OVCA429-CisR and SKOV3-CisR cell lines (**Figure [3](#F3){ref-type="fig"}G-H**). The collective results indicate that Aurora-A inhibition exerts anticancer effects through promoting cell senescence and inhibiting glucose metabolism.

Aurora-A regulates the SOX8/FOXK1 pathway to affect cell senescence and glycolysis in cisplatin-resistant ovarian cancer cells
------------------------------------------------------------------------------------------------------------------------------

To identify the potential targets of Aurora-A in ovarian cancer cells, immunoprecipitation (IP) assay and mass spectrometry analyses were performed. Interestingly, the transcription factor SOX8 was identified as a directly interacting molecule with Aurora-A (**Figure [4](#F4){ref-type="fig"}A-B**), which was further confirmed via co-IP (**Figure [4](#F4){ref-type="fig"}C**) and Fӧrster resonance energy transfer-fluorescence lifetime imaging (FRET-FLIM; **Figure [4](#F4){ref-type="fig"}D-E**). Our data suggest that SOX8 is a potential target of Aurora-A in ovarian cancer.

In view of the finding that Aurora-A is a serine/threonine kinase that functions by phosphorylating proteins, IP and mass spectrometry analyses were conducted, which led to the identification of Ser327 as the phosphorylation site. Immunoblot experiments further confirmed Aurora-A-induced phosphorylation of SOX8 at Ser327. Interestingly, Aurora-A silencing led to reduced accumulation of SOX8 and p-SOX8 (Ser327) proteins mainly in the nucleus, with little effects on the levels of the corresponding cytoplasmic proteins (Ser327; **Figure [4](#F4){ref-type="fig"}F**). Next, we examined the regulatory effect of Aurora-A on p-SOX8 via immunofluorescence in both cell lines and PDOs (**Figure [4](#F4){ref-type="fig"}G-H**). Moreover, data from *in vitro* kinase assays consistently showed that recombinant GST-SOX8 expressed and purified from *Escherichia coli* was phosphorylated at Ser327 by wild-type Aurora-A coprecipitates (**Figure [4](#F4){ref-type="fig"}I**). Finally, we mutated the phosphorylation site in chemoresistant cells and performed immunoblot assay to test the nuclear SOX8 expression level. The results showed that the expression of SOX8 in nuclei was reduced significantly, and functional experiments suggested that the mutant-SOX8 could not rescue the chemosensitivity induced by Aurora-A silencing (**[Figure S5](#SM0){ref-type="supplementary-material"}A-C**).

To further determine whether SOX8 is a critical target gene of Aurora-A, we performed a rescue experiment with overexpression of SOX8 in Aurora-A silencing cells (**[Figure S5](#SM0){ref-type="supplementary-material"}D**) and examined the impacts on cell viability, cisplatin sensitivity, senescence and glycolysis. In both OVCA429-CisR and SKOV3-CisR cell lines, SOX8 overexpression partially reversed the changes in cell viability caused by Aurora-A silencing (**[Figure S5](#SM0){ref-type="supplementary-material"}G**). In addition, Aurora-A silencing-mediated effects on cisplatin sensitivity, senescence, metabolites and glucose consumption were significantly reversed (**[Figure S5](#SM0){ref-type="supplementary-material"}H-J and S6A-F**). Data from qRT-PCR analyses additionally showed that SOX8 transfection partially reversed the changes in cell senescence and glycolysis-associated proteins (**[Figure S5](#SM0){ref-type="supplementary-material"}K, 6G**). In the luciferase reporter assay, SOX8 transfection led to significant inhibition of P16 promoter activity, increase in hTERT promoter activity (**[Figure S5](#SM0){ref-type="supplementary-material"}L-M**), and increase in glycolysis-associated HK2 and LDHA promoter activities (**[Figure S6](#SM0){ref-type="supplementary-material"}H-I**).

To elucidate the mechanistic involvement of SOX8, we transfected two different shRNA vectors of SOX8 into OVCA429-CisR and SKOV3-CisR cell lines (**[Figure S5](#SM0){ref-type="supplementary-material"}E**). RNA sequencing data showed that SOX8 knockdown significantly inhibited FOXK1 expression (**Figure [5](#F5){ref-type="fig"}A**), which was confirmed in cell lines via immunoblotting and immunofluorescence (**Figure [5](#F5){ref-type="fig"}B-C**). qRT-PCR results showed downregulation of FOXK1 mRNA upon knockdown of Aurora-A in both OVCA429-CisR and SKOV3-CisR cells. However, following transfection of SOX8 cDNA, FOXK1 expression was partially rescued (**Figure [5](#F5){ref-type="fig"}D**). Furthermore, a luciferase reporter assay was performed with a FOXK1 promoter luciferase reporter plasmid to determine mechanistic associations among Aurora-A, SOX8 and FOXK1. First, we transfected FOXK1 promoter plasmids into OVCA429-CisR and SKOV3-CisR cell lines with Aurora-A knockdown and overexpression of SOX8. Compared with control groups, Aurora-A silencing led to significant inhibition of FOXK1 promoter activity. However, when cells were transfected with SOX8 cDNA, FOXK1 promoter activity was partially rescued (**Figure [5](#F5){ref-type="fig"}E**). In OVCA429-CisR and SKOV3-CisR cells depleted of SOX8, FOXK1 promoter activity was markedly decreased (**Figure [5](#F5){ref-type="fig"}F**). To confirm the precise SOX8 binding site within the FOXK1 promoter, we cloned promoter fragments of different lengths for analysis of *cis*-acting elements (**Figure [5](#F5){ref-type="fig"}G**). ChIP analysis of SKOV3-CisR cell lines led to the identification of a single binding site located upstream of the transcription start site (**Figure [5](#F5){ref-type="fig"}H**). To further establish the binding site of SOX8, we individually mutated it and repeated the luciferase assay (**Figure [5](#F5){ref-type="fig"}I**). Our results showed that mutation of the binding site alone resulted in abrogation of luciferase activity (**Figure [5](#F5){ref-type="fig"}J**).

To determine the potential functions and mechanisms of action of FOXK1 in chemoresistance, senescence and glycolysis in ovarian cancer cells, OVCA429-CisR/Aur-i1/SOX8 and SKOV3-CisR/Aur-i1/SOX8 cell lines with FOXK1 knockdown were generated (**[Figure S5](#SM0){ref-type="supplementary-material"}F**). In both cell lines, FOXK1 silencing significantly reversed the changes in cell viability induced by SOX8 transfection (**[Figure S5](#SM0){ref-type="supplementary-material"}G**). In addition, FOXK1 knockdown significantly reversed SOX8-mediated cisplatin sensitivity, cell senescence, metabolites and glucose consumption (**Figure S 5H-J and S6A-F**). Similar results were observed with qRT-PCR, whereby FOXK1 knockdown partially reversed the alterations in cell senescence and glycolysis-associated proteins (**[Figure S5](#SM0){ref-type="supplementary-material"}K and S6G**). In the luciferase reporter assay, FOXK1 silencing partially increased the changes in P16 promoter activity, and suppressed the changes in hTERT, HK2 and LDHA promoter activity induced by SOX8 transfection (**[Figure S5](#SM0){ref-type="supplementary-material"}L-M and S6H-I**). Furthermore, ChIP assay was performed to verify the transcriptional regulation (**[Figure S5](#SM0){ref-type="supplementary-material"}N and S6J**).

The above results clearly indicate that Aurora-A contributes to cisplatin resistance by inhibiting cell senescence and promoting glycolysis through regulation of the SOX8/FOXK1 signaling pathway in ovarian cancer.

Aurora-A knockdown inhibits the progression of ovarian cancer and sensitizes cancer cells response to cisplatin *in vivo*
-------------------------------------------------------------------------------------------------------------------------

Tumor promotion and chemoresistance induction functions of Aurora-A *in vivo* were subsequently examined. Firstly, SKOV3-CisR cells with either Aurora-A knockdown or harboring empty vector were injected into flanks of nude mice and tumor sizes were carefully observed. Mice were treated with cisplatin on alternate days when tumor volumes reached 100 mm^3^ (**Figure [6](#F6){ref-type="fig"}A**). As shown in **Figure [6](#F6){ref-type="fig"}B-D**, Aurora-A depletion led to a decrease in the speed of tumor growth and overall tumor weight *in vivo*. Aurora-A silencing in combination with cisplatin treatment induced a further reduction in tumor volume and weight, compared with cisplatin alone. In PET-CT analysis, silencing of Aurora-A strongly suppressed glucose uptake of xenograft cells *in vivo* and resulted in lower SUV~max~ values (**Figure [6](#F6){ref-type="fig"}E-F**). SA-β-gal staining of cisplatin-treated xenograft tissues disclosed that Aurora-A knockdown increased cell senescence (**Figure [6](#F6){ref-type="fig"}G**). Immunofluorescence and qRT-PCR analyses were further employed to validate the relationships among Aurora-A, SOX8 and FOXK1 in the cisplatin treatment groups. Our data showed that Aurora-A knockdown reduced SOX8 and FOXK1 expression in tumors *in vivo* (**Figure [6](#F6){ref-type="fig"}H-I**), with a positive association between SOX8 and FOXK1 expression patterns. Interestingly, Aurora-A silencing indirectly restrained SOX8 transcription, which may be induced by the downregulation of oncogenic transcription factor c-Myc in Aurora-A depleted group (**[Figure S7](#SM0){ref-type="supplementary-material"}A**). Furthermore, SOX8 transcription was effectively rescued by c-Myc overexpression, which was verified via RT-PCR and dual luciferase reporter assay (**[Figure S7](#SM0){ref-type="supplementary-material"}B-C**). In addition, immunofluorescence analyses to determine the associations between Aurora-A and essential proteins involved in cell senescence and glycolysis in xenograft tissues revealed that Aurora-A knockdown after cisplatin treatment reduced hTERT, HK2 and LDHA and increased P16 expression (**[Figure S7](#SM0){ref-type="supplementary-material"}D-G**). Subsequently, mRNA was extracted from transplanted murine tumors and RT-qPCR was performed to validate the involvement of Aurora-A in cell senescence and glycolysis. In accordance with the earlier results obtained with cell lines, Aurora-A depletion enhanced the expression of specific apoptosis- and cell senescence-associated proteins, such as P16 and Rb, and suppressed hTERT as well as proteins involved in glycolysis, such as LDHA, GLUT1, HK2, and SIRT1 (**Figure [6](#F6){ref-type="fig"}J**).

Expression of Aurora-A, SOX8, and FOXK1 is associated with poor survival in ovarian cancer patients
---------------------------------------------------------------------------------------------------

To determine the clinical significance of Aurora-A, SOX8, and FOXK1 in ovarian cancer, we assessed their expression patterns using cisplatin-sensitive and -resistant ovarian cancer tissue microarrays (n = 246 and 185, respectively). Aurora-A was expressed at high levels in 83.24% (154/185) chemoresistant and 64.63% (159/246) chemosensitive ovarian cancer issues. Overall, 75.68% (140/185) chemoresistant ovarian cancer tissues showed high expression of SOX8 relative to 53.25% (131/246) chemosensitive ovarian cancer tissues. We observed \"high\" expression of FOXK1 in 70.81% (131/185) chemoresistant ovarian cancer tissues and 50.81% (125/246) chemosensitive tissues (**Figure [7](#F7){ref-type="fig"}A-B**). High Aurora-A (log-rank P = 0.0007), SOX8 (log-rank P \<0.0001), and FOXK1 (log-rank P = 0.0050) levels were associated with poor OS in chemosensitive ovarian cancer (**[Figure S8](#SM0){ref-type="supplementary-material"}A**). Similarly, high Aurora-A, SOX8, and FOXK1 expression was correlated with poor OS in chemoresistant ovarian cancer (P = 0.0035, 0.0001, and 0.0003, respectively; **[Figure S8](#SM0){ref-type="supplementary-material"}B**). Correlations among Aurora-A, SOX8, and FOXK1 were further confirmed via immunofluorescence (**Figure [7](#F7){ref-type="fig"}C**). Immunohistochemistry, qRT-PCR and immunofluorescence experiments consistently showed that Aurora-A was more highly expressed in chemoresistant tissues and affected expression levels of proteins associated with cell senescence and glycolysis (**Figure [7](#F7){ref-type="fig"}D-E, [Figure S8](#SM0){ref-type="supplementary-material"}C-D**). Our data clearly support involvement of the Aurora-A/SOX8/FOXK1 signaling axis in ovarian chemoresistance (**Figure [7](#F7){ref-type="fig"}F**).

Discussion
==========

RNA sequencing of PDOs initially showed that chemoresistance of ovarian cancer is associated low cell senescence, high glycolysis and high Aurora-A expression. Moreover, Aurora-A appears to exert a regulatory role through direct binding and phosphorylation of the transcription factor SOX8 to activate the SOX8/FOXK1 signaling axis, highlighting this pathway as a novel potential therapeutic target for chemoresistant ovarian cancer.

Conventional research models have failed to recapitulate the nature and heterogeneity of cancer, thereby hampering scientific and clinical progress. Organoids can efficiently replicate many structural and functional aspects of their *in vivo* counterpart organs and have therefore been employed in the development of numerous novel human cancer models [@B24]. For instance, organoids from endometrial pathologies have been shown to successfully replicate the mutational landscape of tumors, along with patient-specific drug responses, disease-associated traits and cancer-linked mutations [@B25]. Moreover, organoid culture offers several advantages in cancer metabolic research [@B10]. Here, we established both cisplatin-sensitive and -resistant ovarian cancer PDOs and employed RNA sequencing, qRT-PCR and immunofluorescence studies to explore the mechanisms underlying chemoresistance of ovarian cancer. Our results collectively suggest that Aurora-A induces chemoresistance via regulation of cell senescence and glucose metabolism pathways.

Aurora A controls centrosome maturation, timing of mitotic entry, assembly of the bipolar spindle, and chromosome alignment in metaphase [@B26] and is associated with aggressive tumor phenotypes [@B20],[@B27],[@B28]. The protein is a key regulatory component of the p53 pathway, phosphorylating p53 at Ser215 and 315, leading to abrogation of p53 DNA binding/transactivation activity and promotion of proteolytic degradation after MDM2-mediated ubiquitination [@B29],[@B30]. The p53 protein exerts its effects by regulating the transcription of genes involved in cell cycle arrest, senescence, apoptosis [@B31], and glycolysis [@B32],[@B33]. However, the specific functions and mechanisms of action of Aurora-A in cell senescence and glucose metabolism remain largely unexplored.

Experiments in the current study demonstrated that Aurora-A strongly reduces cell senescence and increases glucose metabolism, ultimately promoting chemoresistance of ovarian cancer. We showed for the first time that Aurora-A interacts directly with SOX8 and phosphorylates the protein at Ser327 to further regulate the SOX8/FOXK1 axis, which modulates cell senescence and glycolysis, ultimately leading to cisplatin resistance.

In addition, Aurora-A has oncogenic properties in many caners by regulating oncogenic transcription factors. For example, Aurora-A inhibition promoted proteasomal degradation of c-Myc protein through disruption of the c-Myc/Aurora-A complex [@B34]. Our study verified that c-Myc expression was reduced by Aurora-A knockdown in ovarian cancer cells. Furthermore, Aurora-A silencing-mediated low SOX8 transcription was significantly rescued by c-Myc overexpression. Therefore, Aurora-A not only directly phosphorylates SOX8 but also promotes SOX8 transcription indirectly by regulating c-Myc protein.

SOX8 belongs to the Sex-determining region Y-box family of proteins, which are expressed in multiple stem and progenitor cell types and play important roles in the regulation of embryonic development [@B35]. Accumulating evidence supports the importance of SOX genes in drug resistance and EMT. For example, SOX4 is a tumor promoter shown to contribute to drug resistance and progression in cervical cancer and regulate the EMT program in breast cancer [@B36]. While SOX8 is known to regulate cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma through effects on the Wnt/β-catenin pathway [@B37], its functions and mechanisms of action in cancer, particularly ovarian cancer, have rarely been documented. Our results showed that SOX8 targets FOXK1, thereby regulating its transcription, which has significant impacts on senescence, glycolysis and chemoresistance in ovarian cancer.

FOXK1, a member of the FOX family, plays crucial roles in cell proliferation, metastasis, and metabolism [@B38]. Dysregulation of this protein has been reported in various human cancer types, including colorectal cancer [@B39], esophageal cancer [@B40], prostate cancer [@B41] and hepatocellular carcinoma [@B42]. However, the expression patterns and roles of FOXK1 in ovarian cancer have not been established to date. Here, we showed that FOXK1 inhibits cellular senescence and promotes glycolysis and chemoresistance in ovarian cancer through regulating cell senescence- and glycolysis-associated proteins, such as P16, hTERT, HK2 and LDHA. Moreover, high FOXK1 expression was associated with poor survival in ovarian cancer patients.

Several studies suggest that Aurora-A can regulate BRCA1/2 and other DNA repair proteins. For example, Aurora-A suppresses BRCA2-expressing ovarian cancer cells while its silencing restores the level of BRCA2 and increases the number of DNA repair foci of both BRCA2 and Rad51 after γ-irradiation [@B11]. Given that olaparib has been approved as a maintenance drug after platinum-based therapy in recurrent ovarian cancer patients with somatic or germline BRCA mutations [@B43], combination of Aurora-A-targeted therapies and olaparib may present a promising chemotherapeutic strategy to enhance chemosensitivity to olaparib.

Conclusion
==========

In summary, the Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Our findings collectively provide evidence of a novel mechanism underlying the chemoresistance-promoting effects of Aurora-A and present potential therapeutic targets to prevent chemoresistance and progression of ovarian cancer.

Methods
=======

Patients and tissue samples
---------------------------

Tissues microarrays were collected from patients with ovarian cancer in Xinhua Hospital, Shanghai Jiaotong University School of Medical from 2008 to 2018, after obtaining the subjects\' informed consent. The clinical data were shown in **[Table S1](#SM0){ref-type="supplementary-material"}**. For chemotherapeutic response, 185 (42.92%) patients were resistant to platinum-based chemotherapy and 246 (57.08%) were sensitive to the same treatment. PFS was calculated at the time from the date of surgery to the occurrence of progression, or relapse. OS was measured as the length of time from the initiation of surgery to death from any cause or until the most recent follow-up. PFS less than 6 months was defined as resistant to the last chemotherapy, or else it was defined as sensitivity to the last chemotherapy. Our study was approved by the Ethics Committee of the Xinhua Hospital, and each clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki consent.

Organoid formation and culture
------------------------------

Cisplatin-sensitive organoids in our study were generated from cisplatin-sensitive ovarian cancer patients\' tissues in the first surgery. The cisplatin-resistant PDOs were gained from ovarian cancer tissues of the cisplatin-resistant patients, who underwent reoperation after failure of cisplatin-based chemotherapy. Then the PDOs were cultured as described below and the drug resistance tests were performed with the treatment of cisplatin for 21 days.

For PDOs generation, fresh tumor tissues were immediately transported to laboratory in Advanced DMEM/F12 supplement with 1 % penicillin streptomycin after obtained in the surgery. Tissues were diced into approximately 2-3 mm sections and then digested in 37°C for 1 hrs. Digestion solution was made of Advanced DMEM/F12 containing type IV Collagenase (Sigma-Aldrich; catalog number C9407). The digested sample was filtered through a 70-μm filter (Falcon; catalog number 352350). The cell suspension was then spun at 1000 RPM for 5 min to create a cell pellet. The pellet was washed with red blood for 2-3 times. Cells of solid tumor were then mixed with growth factor reduced Matrigel (Corning; catalog number CB-40230C), and cells concentration was 10,000/50 μl\~20,000 cells/50 μl. Once the Matrigel was solidified, 500 μL of general culture medium was added.

Cultures were overlaid with medium containing specific growth factors as the method of Willert [@B44] with a few modifications. PDOs were kept in a humidified atmosphere of 5% CO2 and 95% air at 37 °C, and medium was changed every 2\~3 days.

Senescence-associated beta-galactosidase activity (SA-β-gal)
------------------------------------------------------------

The SA-b-gal activity was widely used for cell senescence test [@B45],[@B46], which was determined using a senescence-associated β-galactosidase assay Kit (Cell Signaling Technology, US) following the manufacturer\'s instructions. Positive SA-b-gal staining cells were counted and the positive rate was calculated in our study to evaluate the level of cell senescence.

Cell lines and culture, and establishment of cisplatin-resistant ovarian cancer cell lines
------------------------------------------------------------------------------------------

Ovarian cancer cells (OVCA429 and SKOV3) were purchased from American Type Culture Collection (ATCC, US). Ovarian cancer cell lines resistant to cisplatin (OVCA429-CisR and SKOV3-CisR) were successfully established by exposing cancer cells to gradually increasing doses of cisplatin *in vitro*. All cells were grown in RPMI-1640 (Gibco BRL) plus 10% fetal bovine serum (Gibco, Life Technologies), and were maintained in a 5% CO2 incubator at 37 °C.

Whole-body ^18^F-FDG positron emission tomography/ computed tomography (PET/CT)
-------------------------------------------------------------------------------

The Whole-body ^18^F-FDG positron emission tomography/ computed tomography imaging was performed as previously described [@B47]. Patients fasted for at least 8 h to ensure low levels of serum glucose. Scanning started 1 h after intravenous injection of the tracer (7.4 MBq/kg). The images were acquired on a Siemens biograph 16HR PET/CT scanner with a transaxial intrinsic spatial resolution of 4.1 mm. Quantification of metabolic activity was acquired using the standard uptake value (SUV) normalized to body weight, and the SUVmax for each lesion was calculated.

Plasmid construction and viral infection
----------------------------------------

To enhance the expression of Aurora-A, human wide type cDNA of Aurora-A was inserted into pCDH (System Biosciences). Lentiviral vectors were produced and used to infect OVCA429 and SKOV3 cells to generate Aurora-A overexpression cell lines: OVCA429/Aur-OE and SKOV3/Aur-OE. The control cell lines were generated by infection of the same cell lines with viruses containing empty vectors (OVCA429/Vector and SKOV3/Vector). Cell lines with SOX8 overexpression were established with the same methods.

In our study, RNA interference technology was used to generate Aurora-A, SOX8 or FOXK1 knockdown cell lines. The control cell lines were generated by infection of lentiviruses harboring scrambled shRNA expression vector (Con). The specific shRNAs against Aurora-A (Aur-i1/2), SOX8 (SOX8-i1/2) or FOXK1 (FOXK1i) were transduced into ovarian cancer cells. The shRNA sequences of Aurora-A were as follows: 5\'-CACATACCAAGAGACCTACAA-3\' (sh1); 5\'-CCTGTCTTACTGTCATTCGAA-3\' (sh2). The shRNA sequences of SOX8 were as follows: 5\'-GCGCTCAAAGCCAAGCCGCAT-3\' (sh1); 5\'-GCCGGCTCACAGGGCGACTAT-3\' (sh2). The shRNA sequences of FOXK1 were depicted below: 5\'-CCAUCAAGAUCCAGUUCAC- 3\' (FOXK1i).

RNA-sequencing data analysis
----------------------------

RNA-sequencing assay was performed as previously described [@B47]. Briefly, a minimum of 1 mg of total RNA was isolated from ovarian cancer cells or organoids and treated with VAHTS mRNA Capture Beads (Vazyme) to enrich polyAþ RNA before constructing RNA libraries. RNA library preparation was performed by using VAHTS mRNA-seq v2 Library Prep Kit from Illumina (Vazyme). Paired-end sequencing was performed with Illumina HiSeq 3000 at RiboBio Co., Ltd. For computational analysis of RNA-sequencing data, sequencing reads were aligned using the spliced read aligner HISAT2, which was supplied with the Ensemble Human Genome Assembly (Genome Reference Consortium GRCh38) as the reference genome. The gene expression levels for each transcript were estimated as the number of reads per kilobase of exon model per million mapped reads (RPKM). Gene Set Enrichment Analysis (GSEA) was used for gene functional annotation. A gene is considered significantly differentially expressed if its expression differs between any two samples with the fold change \> 2 and the p value \< 0.05 as calculated by Cufflinks.

Immunohistochemistry (IHC) assay
--------------------------------

The tissue microarray (TMA) was made by the Xinhua hospital. Immunohistochemistry was performed on 7-mm-thick TMA sections using the antibody against Aurora-A (ab13824, Abcam, 1:100 dilution), SOX8 (ab221053, Abcam, 1:100 dilution) and FOXK1 (ab18196, Abcam, 1:100 dilution). Each case was photographed and scored by two independent pathologists. The immunoreactive score (IRS) was multiplicity of the staining intensity and positive cancer percentage. Finally, the assessment of protein expression was defined as negative (≤1+) and positive (\>2+ to ≤3+).

Detection and quantification of the metabolic profile
-----------------------------------------------------

Metabolites were extracted and analyzed as previously described [@B48]. Briefly, metabolites were extracted from ovarian cancer organoids. Metabolite levels were normalized to the total of all metabolites detected.

Immunoblotting assay
--------------------

For biochemical analysis of tissues or cells, lysates were equilibrated for protein levels using a BCA protein assay kit (Pierce, US) and resolved on 8-12% SDS-PAGE gels depending on the experiment. Nuclear and cytoplasmic fractions were isolated using a NE-PER nuclear and cytoplasmic extraction kit (Thermofisher) under manufacturers\' conditions. The primary antibodies used in immunoblotting experiments were listed in **[Table S2](#SM0){ref-type="supplementary-material"}.**

Quantitative real time PCR (qRT-PCR)
------------------------------------

Total RNA was extracted from cells, organoids or tissue samples with Trizol reagent (Invitrogen, US), and it was reverse transcribed using miScript Reverse Transcription Kit (Qiagen, Germany). The primers for mRNA are listed in **[Table S3](#SM0){ref-type="supplementary-material"}**. The quantification was performed with QuantiTect Probe RT-PCR (Qiagen, Germany). The comparative threshold cycle method was used to determine gene relative expression.

Immunofluorescence assay (IF)
-----------------------------

Cells, organoids or frozen sections of ovarian cancer tissues were fixed with 4% paraformaldehyde for 15 min, and permeabilized with 0.3% Triton X-100 for 15min, followed by blockade with 5% goat serum (Life Technologies, US) for 1 h at room temperature. Then, sections were incubated with primary antibodies overnight at 4°C Secondary antibodies were added, followed by staining with DAPI (Life Technologies, US). Stained sections were imaged using a Leica SP5 confocal fluorescence microscope. The primary antibodies used in IF experiments were listed in **[Table S2](#SM0){ref-type="supplementary-material"}.**

Luciferase reporter assay
-------------------------

Luciferase reporter assay was performed as previously described [@B49]. Cells were transfected with the CRE-luciferase (pGL3 vector), and luciferase activity was measured in the GloMax-Multi Microplate Reader (Promega). Renilla luciferase was used to normalize reporter luciferase activities.

Chromatin immunoprecipitation (ChIP) assay
------------------------------------------

A Pierce Agarose ChIP Kit (Thermo, \#27177) was used for ChIP assay following the manufacturer\'s guidance. Chromatin was mechanically sheared using sonication after SKOV3-CisR cells were collected and crosslinked by formaldehyde and then subjected to immunoprecipitation with 4 mL IgG (Cell Signaling Technology), 10 mL SOX8 (ab 207082, Abcam), or 2 mL Polymerase II (Imgenex) antibodies. Immuno-precipitated and total chromatin was then reverse cross-linked and recovered using column purification. The amount of DNA was further assessed by qRT-PCR, using the FOXK1-specific ChIP primers and SYBR Select Master Mix (Applied Biosystems, Grand Island, NY, USA).

Immunoprecipitation (IP)
------------------------

Immunoprecipitation was performed using Pierce Crosslink Immunoprecipitation Kit (Thermo, \#26147) as per manufacturer\'s protocol. Briefly, cells were lysed in RIPA lysis buffer (25mM Tris-HCl, pH 7.4, 0.15M NaCl, 0.001M EDTA, 1% NP-40, 5% glycerol) in the presence of a protease inhibitor cocktail mixture (Sigma-Aldrich). Cells lysates were pre-cleared by the control agarose resin and then immunoprecipitated using anti-Aurora-A antibody (ab13824, Abcam) overnight at 4°C. Antigen was eluted and subjected to SDS page electrophoresis.

Mass Spectrometry (MS)
----------------------

The Aurora-A-SOX8 complex was obtained by IP with anti-Aurora-A from SKOV3-CisR cells according to the method above. The eluted proteins were resolved on gradient SDS-PAGE, silver stained, and subjected to MS sequencing and data analysis. In-solution and in-gel digestion were performed according to a previously published method [@B50]. Briefly, gel bands were minced and destained with 50% acetonitrile in 50 mM ammonium bicarbonate. Proteins were reduced with 10 mM DTT at 56℃, followed by alkylation with 55 mM iodoacetamide at room temperature in the dark. Trypsin digestion was performed overnight at 37℃ with gentle shaking. Peptides were extracted using 1% trifluoroacetic acid in 50% acetonitrile. Samples were vacuum-dried and reconstituted in 0.1% formic acid for subsequent MS analysis. The treated samples were examined by nanoLC-MS/MS (nanoACQUITY UPLC and SYNAPT G2 HD mass spectrometer, Waters). MS/MS data were obtained with Data Dependent Analysis mode and processed with PLGS 2.4 software (Waters), and the resulting peak list was searched against the NCBI database with the MASCOT search engine. All the Aurora-A-binding proteins tested by MS after IP were listed in **[Table S4](#SM0){ref-type="supplementary-material"}.**

Fӧrster resonance energy transfer-fluorescence lifetime imaging (FRET-FLIM)
---------------------------------------------------------------------------

We performed FRET-FLIM experiments as previously described [@B47]. Briefly, acceptor proteins (fused to RFP) and donor proteins (fused to GFP) were expressed from vector CMV3-C-OFPSpark and pCMV3-C-GFPSpark, respectively. The FRET-FLIM experiments were performed on a Leica TCS SMD FLCS confocal microscope excitation with WLL (white light laser) and emission collected by an SMD SPAD (single photon-sensitive avalanche photodiodes) detector.

*In vitro* kinase assay
-----------------------

Construct for GST-tagged SOX8 was transformed to *Escherichia coli* and induced with 0.1 mM IPTG (Sigma- Aldrich) overnight at 16 °C and then purified using glutathione-Sepharose 4B beads (GE Healthcare). The in vitro kinase assay for wild-type or mutant Aurora-A was carried out as previously described [@B51],[@B52]. The immunoprecipitated Aurora-A was incubated for 15 min with the recombinant GST-SOX8 in phosphorylation buffer supplemented with 2.5 protease and phosphatase inhibitor cocktail (P1045, Beyotime). After denaturation by adding 5×SDS/PAGE sample loading buffer and boiling at 100°C for 5 min, the samples were analyzed by western blotting.

Glycolysis analysis
-------------------

The glycolysis process was tested by the Lactate Colorimetric Assay Kit (BioVision), Glucose Uptake Colorimetric Assay Kit (BioVision), Amplite Colorimetric NADPH Assay Kit (AAT Bioquest Inc.) and ATP Assay Kit (SIGMA ALOR- ICH) following the manufacturer\'s protocols.

Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)
-------------------------------------------------------------------------

Cellular mitochondrial function was measured using the Seahorse XF Cell Mito stress test Kit and the Bioscience XF96 Extracellular Flux Analyzer, according to the manufacturers\' instructions. Glycolytic capacity was determined using the Glycolysis Stress Test Kit as per the manufacturer\'s instructions. Briefly, 4![](thnov10p6928i001.jpg)10^4^ cells were seeded onto 96-well plates and incubated overnight. After washing the cells with Seahorse buffer, 175 mL of Seahorse buffer plus 25 mL each of 1 mmol/L oligomycin, 1 mmol/L FCCP, and 1 mmol/L rotenone was automatically injected to measure the OCR. Then, 25 mL each of 10 mmol/L glucose, 1 mmol/L oligomycin, and 100 mmol/L 2-deoxy-glucose were added to measure the ECAR. The OCR and ECAR values were calculated after normalization to the cell number and were plotted as the mean SD.

Cell counting kit-8 (CCK-8) cell viability assay
------------------------------------------------

The inhibition rate of cell viability was tested by CCK-8. We plated 5 ![](thnov10p6928i002.jpg) 10^3^ cancer cells per well in 96-well plates. The next day, cells were treated with various concentrations of cisplatin (2.5, 5, 10, 20, 40, 80, 160 ug/mL). After 48h the cell viability was tested by CCK-8 (Dojindo Laboratories) according to the manufacturer\'s instructions. Cells were incubated with 10 μl of CCK-8 diluted in normal culture medium at 37°C for 2 h every day, and then OD measurements at 450 nm were tested.

The half-maximal inhibitory concentration (IC50) was calculated by the algebraic formula of the improved Karber method (lgIC50 = Xm-I\[P-(3-Pm-Pn)/4\]; Xm: lg (maximum dose), I: lg (maximum dose / adjacent dose), P: sum of the positive reaction rates, Pm: maximum positive reaction rate, Pn: minimum positive reaction rate). The experiment was repeated three times in triplicate.

Subcellular fractionation
-------------------------

Nuclear and cytosolic fractionation of ovarian cancer cells were obtained by the nuclear and cytoplasmic extraction Kit (Tiangen Biotech) according to the manufacturer\'s instructions.

Flow cytometry
--------------

To determine the levels of apoptosis, cells were treated with 5ug/mL cisplatin for 48h and then collected using trypsin, washed twice with chilled 1xPBS and resuspended in 200 mL binding buffer at a density of 1 ![](thnov10p6928i003.jpg) 10^7^ cells/mL. Next, cells were stained with 5 mL Annexin V and propidium iodide using an apoptosis detection kit (556547, BD Biosciences) and subjected to analysis by flow cytometry (Cytomics FC 500 MPL, Beckman Coulter). Early apoptosis was determined based on the percentage of cells with Annexin V positive, while late apoptotic cells were defined as double positive for PI and Annexin V. Experiments were done at least three times for final analyses.

Mouse studies
-------------

Experimental procedures and animal care in our study were performed following Guidelines for Animal Experiments and were approved by the Ethics Committee at Xinhua hospital. Four-week-old female BALB/c nude mice (Department of Laboratory Animals, Xinhua hospital) were subcutaneously injected with Aurora-A high expression SKOV3-CisR cells and Aurora-A knockdown SKOV3-CisR cells (5 ![](thnov10p6928i004.jpg) 106 cells for each mouse, respectively). Tumor volumes were calculated with the following formula: *V (volume) = L (length)* ![](thnov10p6928i005.jpg)*W (width)^2^* ![](thnov10p6928i006.jpg) Once reaching an average tumor volume of 100 mm^3^, part of the mice were intraperitoneally treated with cisplatin (3 mg/kg). The glucose uptake of the tumor was evaluated by SUVmax of PET/CT scan. Measurement of tumor volume was done every 3 days. Finally, mice were sacrificed and all the tumors were dissected and weighed.

Statistical analysis
--------------------

The data in this study were calculated using GraphPad Prism and reported as mean ± SD. Comparisons between controls and treated groups were determined by paired t test or one-way ANOVA followed by Tukey multiple comparison tests. Clinico-pathologic characteristics analysis was performed using SPSS software (SPSS Standard Version 24.0, SPSS Inc. Chicago, IL). The Kaplan-Meier method with log-rank analyses were used to obtain estimates of OS. Variables with a value of P \< 0.05 in univariate analysis were included in the subsequent multivariate analysis on the basis of the Cox proportional hazards model. A probability less than 0.05 was considered statistically significantly different.
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![**Cisplatin-resistance is closely associated with cell senescence and glucose metabolism in organoids of ovarian cancer. (A)** Images of cisplatin-sensitive and -resistant PDOs of ovarian cancer with 3ug/L cisplatin treatment on days 0 and 21. **(B)** Cell viability assay of PDOs treated with 3 µg/L cisplatin in different time intervals. **(C)** GSEA analysis was performed using cisplatin-sensitive and cisplatin-resistant PDOs of ovarian cancer. The signature was defined by genes with significant expression changes. **(D)** Representative images of β-galactosidase staining in cisplatin-sensitive and cisplatin-resistant ovarian cancer tissues. **(E and F)** The relationship between SUVmax value of PET/CT image and chemosensitivity in ovarian cancer patients. SUVmax value of PET/CT scan in 100 cisplatin-sensitive and 100 cisplatin-resistant ovarian cancer patients were analyzed. **(G)** The association between SUVmax value of PET/CT image and overall survival in ovarian cancer patients. SUVmax value of PET/CT scan in 200 ovarian cancer patients were analyzed. **(H)** Metabolites in glycolysis pathway. **(I) and (J)** Heat map (**I**) and histogram (**J**) of qRT-PCR analysis of indicated genes in cisplatin-sensitive and cisplatin-resistant ovarian cancer organoids. Data were shown as mean ± SD. Significance was calculated using the Student t test. \*P \< 0.05, \*\*P \< 0.01.](thnov10p6928g001){#F1}

![**Aurora-A regulates chemoresistance and cell senescence in ovarian cancer. (A)** GSEA analysis was performed using cisplatin-sensitive and cisplatin-resistant PDOs of ovarian cancer. The signature was defined by genes with significant expression changes. **(B)** Immunofluorescence assay detected the relation of Aurora-A and chemosensitivity in PDOs of ovarian cancer. **(C)** Aurora-A knockdown cell lines were established by immunoblotting. **(D and E)** Values of IC50 of cisplatin. Aurora-A silencing cells, 0.5 nM MLN8237-treated cells and their controls were treated with cisplatin in different concentrations for 48h. \*\*P \< 0.01. **(F) and (G)** Percentage of apoptotic cells. Except the blank group, cells were treated with 5 µg/mL cisplatin, 0.5nM MLN8237, or 5 µg/mL cisplatin plus 0.5 nM MLN8237 for 48 h, respectively. Apoptosis was measured by flow cytometry in cells stained with annexin V and propidium iodide. \*\*P \< 0.01. **(H and I)** β-galactosidase staining. \*\*P \< 0.01. Cells were treated with the same method as Figure [2](#F2){ref-type="fig"}F-G. **(J)** Immunoblotting analysis of proteins associated with the cell senescence and apoptosis.](thnov10p6928g002){#F2}

![**Aurora-A modulated the glucose metabolism in ovarian cancer cells. (A-D)** Glucose uptake (**A**), ATP (**B**), lactate (**C**) and NADPH (**D**) production were determined as described in Methods. "CON" was the cells transfected with scrambled shRNA expression vector. Data shown were mean ± SD of triplicate measurements repeated 3 times with similar results. Statistical significance was assessed by two-tailed Student\'s t test. **(E and F)** ECAR (**E**) and OCR (**F**) were determined as described in Methods. **(G)** Immunoblotting analysis of glycolytic gene expression in Aurora-A knockdown ovarian cancers and the controls. **(H)** Immunofluorescence assay detected the relationship between Aurora-A and glycolysis associated proteins.](thnov10p6928g003){#F3}

![**Aurora-A combined with SOX8 directly and activated it by phosphorylation. (A)** Cellular extracts from SKOV3-CisR cells were immunopurified with anti-Aurora-A affinity columns and eluted with Aurora-A peptide. The eluates were resolved by SDS-PAGE and silver stained. **(B)** Mass spectrometry analysis of the SDS-PAGE above. The detected peptides spectra of SOX8 were listed. **(C)** Co-IP analysis demonstrated an interaction between Aurora-A and SOX8 protein in OVCA429-CisR and SKOV3-CisR cell lines. **(D and E)** Interaction between Aurora-A and SOX8 confirmed by FRET-FLIM upon transient co-expression. FE, FRET efficiency. \*\*P \< 0.01. **(F)** Aurora-A silencing significantly changed the distribution and expression of SOX8 and p-SOX8 (Ser327) in cytoplasm and nucleus of ovarian cancer cells. **(G and H)** Immunofluorescence assay detected the relation of Aurora-A and p-SOX8 (Ser327) in ovarian cancer cell lines (**G**) and PDOs (**H**). **(I)** In vitro kinase assay to detect the phosphorylation of recombinant GST-SOX8 protein by wild-type or mutant Aurora-A coprecipitates.](thnov10p6928g004){#F4}

![**FOXK1 is the downstream targeting molecule of SOX8. (A)** GSEA analysis was performed using SOX8 knockdown cell line and the control (SKOV3-CisR/SOX8-i1 and SKOV3-CisR/Con). The signature was defined by genes with significant expression changes. **(B and C)** Immunoblotting and immunofluorescence assay detected the relation of SOX8 and FOXK1 in ovarian cancer cells. **(D)** FOXK1 mRNA expression level in Aurora-A knockdown ovarian cancer cell lines and SOX8 transfected cell lines in rescue experiment. **(E)** FOXK1 promoter activity affected by Aurora-A knockdown and SOX8 overexpression.**(F)** FOXK1 promoter activity affected by SOX8 silencing.**(G)** The region of SOX8 binding sites within the FOXK1 promoter. **(H)** ChIP results of the binding of SOX8 to the promoter of FOXK1.**(I)** The map of SOX8 binding sits in the promoter region of FOXK1. **(J)** Luciferase reporter assay was used for the detection of mutant sites in the promoter region of FOXK1. \*\*P \< 0.01.](thnov10p6928g005){#F5}

![**Aurora-A knockdown inhibited the progression of ovarian cancer and sensitized cancer cells response to cisplatin *in vivo*. (A)** Flow chart of the *in vivo* experiment. **(B)** Representative image of nude mice bearing tumors formed by SKOV3-CisR/Aur-i1 and their control cells with cisplatin treated or untreated. **(C)** Growth curve of the xenograft tumors burdened in mice. **(D)** The average tumor weight of nude mice.**(E)** Average SUVmax values of nude mice bearing tumors.**(F)** Representative image of PET-CT, which was used for the detection of glucose uptake. **(G)** Representative image of β-galactosidase staining of the nude mice tumor tissues with or without cisplatin treatment. **(H)** Immunofluorescence assay detected the relation among Aurora-A, SOX8, and FOXK1 in the nude mice tumor tissues with cisplatin treatment.**(I)** The mRNA expression levels of Aurora-A, SOX8, and FOXK1 were tested by qRT-PCR assay in tumors*in vivo.* Error bars: 95% Cis; \*\*P \< 0.01. **(J)** Heat map showed the gene expression associated with cell senescence and glycolysis in the nude mice tumor tissues with cisplatin treatment.](thnov10p6928g006){#F6}

![**Immunohistochemistry staining and immunofluorescence of Aurora-A, SOX8, FOXK1 and proteins related to glycolysis and cell senescence. (A)** Representative images of immunohistochemistry staining of Aurora-A, SOX8, and FOXK1 in cisplatin-sensitive and cisplatin-resistant ovarian cancer tissues. **(B)** Relatively high or low expression ratio of Aurora-A, SOX8 and FOXK1 in cisplatin-sensitive and cisplatin-resistant ovarian cancer samples. **(C)** Immunofluorescence staining of Aurora-A, SOX8 and FOXK1.**(D)** Immunohistochemistry of Aurora-A and the proteins associated with cell senescence and glycolysis. **(E)** The mRNA expression levels of genes associated with cell senescence and glycolysis were tested by qRT-PCR assay. **(F)** Schematic model showing the role of the Aurora-A/SOX8/FOXK1 signaling axis in the regulation of cell senescence, glycolysis and chemosensitivity.](thnov10p6928g007){#F7}

[^1]: \*These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
